Article Text
Abstract
Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for mUC has seismically shifted following the approval of five therapies targeting the programmed cell death protein (PD-1)/programmed cell death ligand 1 (PD-L1) axis. Notably, the anti-PD-1 antibody pembrolizumab demonstrated improved OS relative to chemotherapy in a randomized phase III study for second line treatment of mUC; this level 1 evidence led to approval from the U.S. Food and Drug Administration (FDA). The PD-1 antibody nivolumab also demonstrated an overall survival benefit, in this case in comparison to historical controls. Similarly, antibodies targeting PD-L1 including atezolizumab, durvalumab, and avelumab have now received accelerated approval from the FDA as second line treatments for mUC, with durable response lasting more than 1 year in some patients. Some of these agents are approved in the first line setting as well - based on single-arm phase II studies atezolizumab and pembrolizumab received accelerated approval for first-line treatment of cisplatin ineligible patients. Despite these multiple approvals, the development of clinically useful biomarkers to determine the optimal treatment for patients remains somewhat elusive. In this review, we examine key clinical trial results with anti-PD1/PD-L1 antibodies and discuss progress towards developing novel biomarkers beyond PD-L1 expression.
- Bladder cancer
- PD-1
- Pd-L1
- Immunotherapy
- Atezolizumab
- Nivolumab
- Pembrolizumab
- Avelumab
- Durvalumab
- Tumor mutation burden
- Immune checkpoint inhibitor
- Biomarker
- Nanostring
- AE
- Adverse event
- CI
- Confidence interval
- FDA
- Food and Drug Administration
- IC
- Immune cell
- IHC
- Immunohistochemistry
- MSI
- Microsatellite instability
- mUC
- Metastatic urothelial cancer
- NSM
- Non synonomous mutation
- ORR
- Objective response rate
- OS
- Overall survival
- PD-1
- Programmed cell death protein 1
- PD-L1
- Programmed death ligand 1
- PFS
- Progression-free survival
- TC
- Tumor cell
- TCGA
- The Cancer Genome Atlas
- TMB
- Tumor mutation burden
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.